Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4252W HIGH $8.51
Volume
5.00 K
Value Traded
396.55 K
Short % Float
9.71%
-4.65%Week
-20%1 Month
-35.43%3 Month
+3.47%6 Month
-93.47%5 Year
-94.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
107.04 M
EPS (TTM)
-1.51
P/E Ratio
-
Ent. Value
89.58 M
Total Shares
32.72 M
Float Shares
10.22 M
Insiders
68.77%
Institutions
17.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IMDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Insight Molecular Diagnostics Inc.
Past FDA Catalysts and PDUFA Decisions
How IMDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Insight Molecular Diagnostics Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IMDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| atezolizumab | triple negative breast cancer (TNBC) | Phase 3 | 2021-09-20 | DetermaIO outperformed 80 other immune related signatures; IO score demonstrated the ability to identify those TNBC patients who benefitted the most from the addition of atezolizumab; IO score was significantly more associated with pCR in atezolizumab arm than any other immune-related signaturesRead More | Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SILVERMAN LOUDirector | Disposition | -7,700 55,807 held | $5.69 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IMDX for Q2 2026. | ||||
IMDX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMDX ranks across every disease it competes in
Competitive Position is a premium feature
See how IMDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMDX News
IMDXiMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
Insight Molecular Diagnostics Inc. (IMDX) will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026. CEO Josh Riggs and CFO Andrea James will represent the company in one-on-one meetings with investors at the Metropolitan Club in New York City. This event aims to enhance investor engagement and showcase the company's innovative diagnostics technology.
Read more →IMDXiMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
Insight Molecular Diagnostics Inc. (iMDx) will announce its second quarter 2026 financial results on August 10, 2026, followed by a live webinar for discussion. Additionally, CEO Josh Riggs and CFO Andrea James will attend the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, conducting one-on-one meetings with investors.
Read more →IMDXiMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
iMDx has announced a new study published in The Lancet Regional Health that highlights the effectiveness of donor-derived cell-free DNA (dd-cfDNA) monitoring in guiding treatment for kidney transplant patients. The study supports the use of iMDx's GraftAssure technology, which has received Medicare reimbursement coverage. This development indicates a significant market opportunity for iMDx as it seeks to expand the clinical applications of its testing technology.
Read more →IMDXFavorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
Insight Molecular Diagnostics Inc. (IMDX) announced a favorable Medicare policy that expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy supports the commercial adoption of iMDx's GraftAssure assay portfolio by providing reimbursement clarity and increasing testing frequency for kidney and heart transplant patients. The policy is expected to enhance patient access to critical monitoring tests.
Read more →IMDXIMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Insight Molecular Diagnostics Inc. announced that Chief Science Officer Prof. Dr. Ekkehard Schuetz has published his 200th research paper, solidifying his status as a leading figure in laboratory diagnostics. His contributions include advancements in molecular diagnostic testing for organ rejection and the development of the GraftAssure technology. This milestone highlights both his extensive experience and the ongoing innovation at iMDx.
Read more →IMDXiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
iMDx and the American Society of Transplant Surgeons have announced the recipients of the ASTS-iMDx Health Economics Research Grant. The grant has been awarded to Dr. Kenneth Andreoni and Dr. Kenneth Chavin for their contributions to understanding health economics in transplantation. This collaboration aims to enhance research in the field.
Read more →IMDXFavorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Insight Molecular Diagnostics Inc. announced the publication of a favorable study in Clinical Chemistry, comparing its GraftAssure test to a competing NGS assay. The study found a 99.2% agreement in assessing kidney transplant rejection risk, highlighting GraftAssure's enhanced sensitivity and potential for improved patient care. The findings support the integration of dd-cfDNA testing into clinical practice.
Read more →IMDXIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
Insight Molecular Diagnostics Inc. announced that its GraftAssure assay has been published in the American Journal of Transplantation, demonstrating superior diagnostic performance in kidney transplant rejection monitoring. The CM-Score significantly improves the positive predictive value to over 80% and retains a high negative predictive value. The company is pursuing FDA marketing authorization for its test kits to enhance local transplant center capabilities.
Read more →IMDXiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Insight Molecular Diagnostics Inc. (IMDX) will showcase its GraftAssure technology at the American Transplant Congress in Boston. The company aims to highlight the benefits of in-house organ rejection testing and announce grant winners for research on testing economics. iMDx is seeking FDA authorization for its GraftAssureDx kit, which promises faster, more affordable testing.
Read more →IMDXIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Insight Molecular Diagnostics Inc. (IMDX) reported strong progress in Q1 2026 towards the commercialization of its GraftAssureDx kidney transplant monitoring assay. The company is engaging with major transplant centers and has received positive feedback from the FDA regarding its regulatory submission. Despite a net loss of $4.3 million, the company anticipates significant orders following FDA authorization later in 2026.
Read more →IMDX▲ +9.8%on this news
iMDx to Release First Quarter 2026 Results on May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) will announce its first quarter 2026 financial results on May 13, 2026, after market close. A live Zoom webinar will follow at 2:00 PM PT to discuss these results and include a Q&A session. An archived replay will be available on the company's website.
Read more →IMDXInsights Into the 2026 Fallopian Tube Cancer Therapeutics Market: Targeted Treatments and Early Diagnosis Fuel Market Expansion
The global fallopian tube cancer therapeutics market is set for substantial growth, expected to rise from USD 1.95 billion in 2025 to USD 5.54 billion by 2035, reflecting a compound annual growth rate of 11%. This expansion is attributable to increased focus on targeted treatments, rising awareness of gynecological cancers, and advancements in diagnostic methods. Key market players are enhancing their positions through strategic collaborations and expanding product portfolios, despite challenges such as high costs and disparities in healthcare infrastructure that may restrict therapy access. The market features significant advancements in early diagnosis and innovation in treatment options, such as PARP inhibitors.
Read more →IMDX▲ +20.3%on this news
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
Insight Molecular Diagnostics Inc. (IMDX) announced positive real-world data for its GraftAssure assay, which will be showcased at several upcoming international conferences. The company is also hosting a fireside chat at the Needham Virtual Healthcare Conference. Despite a solid cash balance, iMDx remains pre-revenue and awaits FDA approval for its GraftAssureDx assay.
Read more →IMDX▼ -13.4%on this news· ran to -38% by day 1
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
Insight Molecular Diagnostics Inc. has submitted GraftAssureDx, the first kitted dd-cfDNA assay, for FDA review. The company reports increased interest from transplant centers, with 37 engaged in the U.S. alone. They anticipate a 150-day review process and are preparing for potential FDA queries. The assay aims to revolutionize organ rejection monitoring and management.
Read more →IMDX▲ +8.7%on this news
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Insight Molecular Diagnostics Inc. (iMDx) will announce its fourth quarter 2025 financial results on March 26, 2026, followed by a live webinar for discussion. Additionally, CEO Josh Riggs and CFO Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, engaging in one-on-one meetings with investors.
Read more →IMDXSecond Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc. has published a new peer-reviewed study affirming the superiority of its GraftAssure assay technology in kidney transplant monitoring. The study demonstrated that the proprietary Combination Model score outperformed traditional dd-cfDNA measures, indicating its potential for better predicting transplant rejection. This research supports iMDx's commercialization strategy and aims to enhance access to organ health testing for kidney transplant patients.
Read more →IMDX▲ +10.3%on this news
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
Insight Molecular Diagnostics has completed significant milestones for its GraftAssureDx test kit, including a three-site reproducibility study and the collection of sufficient clinical samples for FDA submission. The company also received ISO 13485 certification, enabling regulatory submissions in the U.K. and E.U. The firm aims to enhance organ health testing for kidney transplant patients.
Read more →IMDX▼ -22.7%on this news
iMDx Announces $26.0 Million Registered Direct Offering
Insight Molecular Diagnostics Inc. has announced a registered direct offering of 4,525,976 shares at $5.75 per share, expected to close on February 12, 2026. The offering aims to raise approximately $26 million for general corporate purposes, particularly to expand its GraftAssure product line into heart transplant rejection testing. Bio-Rad Laboratories, a significant shareholder, is participating in the offering.
Read more →IMDX▼ -22.7%on this newsshared move
Insight ANNOUNCES $26.0 MILLION REGISTERED DIRECT OFFERING
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) announced a registered direct offering for the sale of 4,525,976 shares of its common stock at a price of $5.75 per share, expected to close on February 12, 2026. The offering aims to raise approximately $26 million to support general corporate purposes, including research and development in transplant diagnostics. The company intends to enhance its GraftAssure product line particularly focusing on heart transplant rejection testing. Street Capital Markets, LLC is acting as the sole placement agent for the offering.
Read more →About Insight Molecular Diagnostics Inc.
Headquarters2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
BIOPHARMAWATCH ELITE PLUS
Trade the next IMDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime